Antibody, Gene Silencing and Pharma Companies

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Antibody

Gene Silencing

Pharma Companies

Unfolding The Folds Of Transthyretin

Delveinsight

AUGUST 6, 2020

Gene-silencing Therapies. Silencing or modifying gene TTR aims to reduce the effect of both variant and wild-type TTR gene, thus reducing hepatic production by targeting its mRNA. The past years have witnessed a shift from off-label and symptomatic therapies to approved TTR stabilizers and gene-silencing therapies.

Gene Silencing

Gene Silencing Protein Marketing Gene

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

DECEMBER 23, 2020

Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. In summer, Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder Oxlumo was approved in the European Union and the US.

Marketing

Marketing Gene Silencing Gene Drugs

Clinical Research Informer

Unfolding The Folds Of Transthyretin

2020 review – Pharma’s progress outside of COVID-19

Stay Connected